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ABSTRACT
Although our antifungal armamentarium has been enlarged recently with new azoles (voriconazole and
posaconazole) and echinocandins (caspofungin, micafungin, anidulafungin), the polyenes still have an
important role in antifungal strategies because of their extended antifungal spectrum and rarity of
mycological resistance. The use of conventional amphotericin B deoxycholate is limited by substantial
toxicity that is either infusion-related or associated with renal failure. Its lipid derivatives, particularly
liposomal amphotericin B (LAmB), are less nephrotoxic while maintaining a broad antifungal spectrum.
LAmB is active against most Candida spp., including Candida glabrata and Candida parapsilosis, and
against more resistant, emerging yeasts species such as Rhodotorula spp., Geotrichum spp. and
Trichosporon spp.. LAmB is also active against Cryptococcus spp. and all dimorphic fungi such as
Histoplasma, Blastomyces, Coccidioidomyces, and Paracoccidiodomyces. The antifungal spectrum of LAmB is
particularly interesting with regard to filamentous fungi, with marked activity against Aspergillus spp.
and agents of zygomycosis. The latter might emerge during long-term treatment with voriconazole or an
echinocandin, as these organisms are resistant to these drugs. We review here the role of LAmB in the
current antifungal management strategy, which is based on results obtained in prospective trials. LAmB
can be retained as first-line treatment for human immunodeficiency virus (HIV)-positive patients with
disseminated histoplasmosis and cryptococcosis, even in the setting of renal impairment or concomitant
administration of potentially nephrotoxic drugs. In addition, there is sufficient evidence that the drug
should be a major consideration for the empirical treatment of persistent febrile neutropenia or as an
alternative to for patients with invasive aspergillosis, for those at risk of renal impairment, major drug–
drug interaction or liver insufficiency, particularly in the situation of an established azole intolerance.
The primary licensed indication for LAmB is empirical treatment. When zygomycosis is suspected or
has been documented, high doses of LAmB should be prescribed. Finally, LAmB may also be considered
as a therapeutic option for the management of candidaemia and remains a cornerstone for the treatment
of some visceral localisations during systemic candidosis.
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INTRODUCTION
Although our antifungal armamentarium has
been expanded recently with new azoles (voric-
onazole and posaconazole) and echinocandins
(caspofungin, micafungin, anidulafungin), poly-
enes still have an important role in antifungal
management strategies because of their broad
antifungal spectrum and rarity of resistance. The
use of conventional amphotericin B deoxycholate
(AmBD) is limited by substantial toxicity that is
either infusion-related or associated with renal
failure. Its lipid derivatives, particularly liposo-
mal amphotericin B (LAmB), are less nephrotoxic
while maintaining the broad antifungal spectrum.
LAmB is active against most Candida spp., includ-
ing Candida glabrata, which can be less susceptible
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or resistant to fluconazole, and Candida parapsilo-
sis, which appears to be intrinsically less suscep-
tible to the echinocandins. Some emerging yeast
species demonstrate greater resistance: Rhodotor-
ula is frequently resistant to fluconazole and
voriconazole [1], and Geotrichum and Trichosporon
are not susceptible to echinocandins. LAmB is
also active against Cryptococcus spp. and all
dimorphic fungi, including Histoplasma, Blastomy-
ces, Coccidioidomyces, and Paracoccidioidomyces. The
antifungal spectrum of LAmB is particularly
interesting with respect to filamentous fungi,
since it shows marked activity against Aspergillus
spp. and Zygomycetes. The latter microorganisms
might indeed emerge, particularly during long-
term voriconazole or echinocandin therapy, as
they are resistant to both voriconazole and ech-
inocandins. We will review here the role of LAmB
in current antifungal management strategies
based on prospective trials that assessed the
potential of LAmB in the treatment of invasive
mycoses (Table 1).
LIPOSOMAL AMPHOTERICIN B FOR
THE TREATMENT OF CANDIDOSIS
Species of Candida other than Candida albicans
and ⁄ or fluconazole-resistant Candida strains have
been held responsible for infections in humans
since 1990 [2]. When the data from several recent
epidemiological studies are pooled, one might
arrive at the conclusion that C. albicans represents
c. 55% of all Candida spp. isolated from blood
cultures, C. glabrata 15%, C. parapsilosis 15% and
Candida tropicalis 9%. Two per cent of C. albicans
and 10% of non-albicans Candida strains isolated
from blood cultures are fluconazole-resistant [3,4].
AmBD has been shown to be effective for the
management of candidaemia, including infections
due to fluconazole-resistant Candida spp.. AmBD
is active against most Candida spp., including
C. glabrata, which can be resistant to voriconazole
and posaconazole in vitro [5], and C. parapsilosis,
which appears to be intrinsically less susceptible
to echinocandins.
Recent randomised studies that compared
AmBD with voriconazole and caspofungin
showed that the efficacy of these new antifungal
drugs was similar to that of AmBD in the
treatment of candidaemia and ⁄ or invasive cand-
idosis. Mora-Duarte et al. compared caspofungin
with AmBD in the treatment of candidaemia or
invasive candidosis in both neutropenic and non-
neutropenic adults [6]. Therapy with AmBD was
accompanied by a higher toxicity with more
adverse events in comparison with caspofungin
(58% vs. 29%). Kullberg et al. compared vorico-
nazole with AmBD for the treatment of candida-
emia in non-neutropenic adults and they also
found therapy with AmBD to be more toxic than a
voriconazole-based regimen (overall rate of ad-
verse events being 51% vs. 36%) [7]. Such
observations point to the conclusion that not
insufficient activity, but rather major immediate
and ⁄ or renal toxicity, constitutes the major limit-
ing factor of AmBD in the management of
candidosis.
The efficacy of LAmB was first studied in
invasive candidosis in 1991. Twenty-five patients
with heterogeneous underlying diseases were
treated with LAmB 0.5–5 mg ⁄kg ⁄day as second-
line treatment after intolerance of or failure with
AmBD; 76% of patients were finally cured [8].
LAmB was further studied in 44 neonates and
preterm infants with invasive candidosis, and a
73% response rate was achieved [9]. LAmB was
also evaluated in the treatment of systemic cand-
idosis among very low birth weight infants: 24
infants were treated with 2.5–7 mg ⁄ kg ⁄day
LAmB, and an 83% response rate was achieved
at the end of treatment [10]. In another small, non-
randomised study, LAmB was compared with
AmBD in premature infants with candidaemia.
Thirty-four infants with normal renal function
were treated with AmBD at a dose of
1 mg ⁄ kg ⁄day for at least 14 days; six with altered
renal function were given 5 mg ⁄ kg ⁄day LAmB,
and another 16 with altered renal function
received 3 mg ⁄ kg ⁄day amphotericin B colloidal
dispersion (ABCD). Clearance of fungaemia was
achieved in 68% of patients treated with AmBD,
as compared to 83% among patients on LAmB
and 57% on ABCD [11]. LAmB thus appeared to
be at least as efficacious as AmBD in the treatment
of candidaemia in neonates and infants.
In a recently published randomised, double-
blind non-inferiority trial, 3 mg ⁄ kg ⁄day LAmB
was compared with 100 mg ⁄day micafungin as
first-line treatment of candidaemia and invasive
candidosis. Antifungal therapy was given for at
least 14 days to 537 neutropenic and non-neu-
tropenic patients [12]. The success rate for both
micafungin and LAmB was 90%, and this striking
similarity was independent of the Candida spp.
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Table 1. Prospective therapeutic trials evaluating liposomal amphotericin B for the management of invasive fungal infections and visceral leishmaniasis (1991–2007)
Reference
Study
design Treatment groups
Patient
number
Duration
of
treatment
Response
at end of
therapy
Breakthrough
fungal
infection Survival
Candidiasis [8] IC, second-line treatment MC LAmB 0.5–5 mg ⁄ kg ⁄day 25 18 days 76% cured _ NA
[9] IC in neonates and preterms,
first-line treatment
SC LAmB 1–5 mg ⁄ kg ⁄day 44 22 days 73% _ 64%
[10] IC in very low birth weight infants,
first- or second-line treatment
MC LAmB 2.5–7 mg ⁄ kg ⁄day 24 2 weeks 83% _ 83%
[12] Candidaemia and IC, first-line
treatment
MC, R, DB LAmB 3 mg ⁄ kg ⁄day
Micafungin 100 mg ⁄day
202
190
2 weeks 89.6%
89.5%
_ 60% (week 12)
60% (week 12)
[11] Candidaemia in premature infants,
first-line treatment
SC LAmB 5 mg ⁄ kg ⁄day
ABCD 3 mg ⁄ kg ⁄day
AmBD 1 mg ⁄ kg ⁄day
6
16
34
2 weeks 83.3%
57.1%
67.6%
_ 83%
88%
85%
Aspergillosis [8] Proven IA, second-line treatment MC LAmB 0.5–5 mg ⁄ kg ⁄day 28 29 days 32% cured _ NA
[21] IA and neutropenia, first-line
treatment
MC, R LAmB 1 mg ⁄ kg ⁄day
LAmB 4 mg ⁄ kg ⁄day
41
46
2 weeks 64%
48%
_ 43% (month 6)
37% (month 6)
[20] IFI (53 IA), first-line treatment MC, R LAmB 5 mg ⁄ kg ⁄day
AmBD 1 mg ⁄ kg ⁄day
25
28
2 weeks 52%
29%
_ 78%
62%
[23] IFI (95% IA) ‘Ambiload’ trial MC, R, DB LAmB 3 mg ⁄ kg ⁄day
LAmB 10 mg ⁄ kg ⁄day
107
97
2 weeks 50%
46%
_ 72% (week 12)
59% (week 12)
[25] IA, first-line treatment MC, R LAmB 10 mg ⁄ kg ⁄day
LAmB 3 mg ⁄ kg ⁄day +
caspofungin
15
15
17 days 27%
67%
_ 82% (week 12)
100% (week 12)
Histoplasmosis [28] Disseminated in patients
with AIDS
MC, R, DB LAmB 3 mg ⁄ kg ⁄day
AmBD 0.7 mg ⁄ kg ⁄day
55
26
2 weeks 88%
64%
_ 98%
83%
Cryptococcosis [33,68] Cryptococcal meningitis
and AIDS
MC, R LAmB 4 mg ⁄ kg ⁄day
AmBD 0.7 mg ⁄ kg ⁄day
15
13
3 weeks 86%
80%
_ 93%
85%
Unpublished Cryptococcal meningitis
and AIDS
MC, R, DB LAmB 3 mg ⁄ kg ⁄day
LAmB 6 mg ⁄ kg ⁄day
AmBD 0.7 mg ⁄ kg ⁄day
267 2 weeks 64%
54%
54%
_ 87%
84%
Febrile neutropenia [4949] Febrile neutropenia MC, R, DB LAmB 3 mg ⁄ kg ⁄day
AmBD 0.6 mg ⁄ kg ⁄day
343
344
Neutropenia 50%
49%
3%
8%
93% (day 7)
90% (day 7)
[50] Febrile neutropenia MC, R, DB LAmB 3 mg ⁄ kg ⁄day
VRZ 6 mg ⁄ kg twice-daily
D1, 3 mg ⁄ kg twice-daily
422
415
3 days after
neutropenia
resolution
31%
26%
5%
1.9%
94% (day 7)
92% (day 7)
[51] Febrile neutropenia MC, R, DB LAmB 3 mg ⁄ kg ⁄day
Caspofungin 70 mg ⁄day,
50 mg ⁄day
539
556
7 days after
neutropenia
resolution
34%
34%
4%
5%
86% (day 7)
89% (day 7)
[13] Febrile neutropenia MC, R, DB LAmB 3 mg ⁄ kg ⁄day
LAmB 5 mg ⁄ kg ⁄day
ABLC 5 mg ⁄ kg ⁄day
85
81
78
3 days after
neutropenia
resolution
42%
40%
33%
3%
2%
4%
2.5%
14.1%
IFI prophylaxis Unpublished AL
ASCT
MC LAmB 10 mg ⁄ kg ⁄week 15
8
4 weeks
8 weeks
AE: 2.9 ⁄patients
AE: 7.2 ⁄patients
NA 86% (month 6)
75% (month 6)
[61] ACST acute GVHD SC LAmB 7.5 mg ⁄ kg ⁄week 21 8 weeks AE: 33% 5% 62%
[62] ACST children MC LAmB 3 mg ⁄ kg ⁄day 51 100 days Dose decrease:
30%
Treatment
interruption: 11%
IFI: 9.7%
IMI: 0%
81% (month 3)
Visceral leishmaniasis [65] VL MC LAmB 4 mg ⁄ kg ⁄day, days 1–5, day 10
LAmB 3 mg ⁄ kg ⁄day, days 1–5, day 10
LAmB 3 mg ⁄ kg ⁄day, days 1–4, day 10
13
42
32
100%
98%
91%
_ 100%
[64] VL MC, R LAmB 1 mg ⁄ kg ⁄day
LAmB 5 mg ⁄ kg
45
46
5 days
1 days
93%
91%
_ 100%
[66] VL MC LAmB 7.5 mg ⁄ kg 203 1 day 96% – 99%
MC, multicentre; SC, single centre; R, randomised; DB, double blind; VRZ, voriconazole; LAmB, liposomal amphotericin B; AmBD, amphotericin B deoxycholate; AE, adverse event; IFI, invasive fungal infection; IMI, invasive mould
infection; IA, invasive aspergillosis; IC, invasive candidosis; VL, visceral leishmaniasis; AL, acute leukaemia; ASCT, allogeneic stem cell transplant; GVHD, graft vs. host disease; ABCD, amphotericin B colloidal dispersion; ABLC,
amphotericin B lipid complex; NA, non available; Dl, day 1.
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involved and the neutropenia status. Survival was
similar in both arms of the trial and was 60% at
week 12, whereas treatment-related adverse
events were seen more frequently in the LAmB
group: rigors (0.8% vs. 6.4%), infusion-related
reactions (17% vs. 28.8%), and creatinine eleva-
tions (10.3% vs. 29.9%); hypokalaemia was also
more prevalent in patients receiving LAmB (6.8%
vs. 12%).
A study of Wingard and colleagues demon-
strated that LAmB is better tolerated than is
amphotericin B lipid complex (ABLC), the other
widely commercialised amphotericin B lipid for-
mulation in Europe, in relation to both fever (23%
vs. 57%) and chills (19% vs. 80%) [13]. Nephro-
toxicity was seen more commonly in patients
treated with ABLC as compared to LAmB (14%
vs. 42% respectively). The authors’ conclusion,
highlighting an improved safety profile for LAmB
as compared with AmBD, is shared by Ostrosky-
Zeichner and colleagues, who argue that LAmB
might be used as a better option to treat candi-
daemia when polyenes are seriously considered
as an alternative for fluconazole, i.e., for severe
sepsis, and for patients with neutropenia, a
history of recent treatment with an azole anti-
fungal and the possibility of fluconazole-resistant
Candida spp. [14].
According to the 2004 guidelines published by
the Infectious Diseases Society of America (IDSA),
fluconazole is recommended for the treatment of
candidaemia and disseminated candidiasis as
first-line treatment for clinically stable patients
who have not recently received azole treatment.
For other patients, AmBD and caspofungin are
mentioned as preferred treatment options [15]. A
dose of 3 mg ⁄kg ⁄day of LAmB is advocated for
patients at high risk of being intolerant to AmBD
(renal dysfunction or concomitant use of poten-
tially nephrotoxic agents). UK guidelines recom-
mend either fluconazole or AmBD as standard
treatment for candidaemia, whereas LAmB is
considered to represent a useful alternative [16],
whereas French guidelines recommend LAmB for
the treatment of candidaemia in cases of renal
impairment or administration of at least two
concomitant nephrotoxic drugs [17]. Caspofungin
can also be used in this context. The 2007 update
of the ECIL Guidelines for Antifungal Therapy in
Leukemia Patients has given LAmB the highest
recommendation (A1), similar to that for caspo-
fungin, where the species had been identified.
Treatment guidelines for meningitis, endocar-
ditis presumably caused by Candida spp. and
hepatosplenic candidosis rely on observational
studies. The recommended treatment for menin-
gitis is a combination of AmBD or LAmB with
flucytosine. Such a combination has become
popular on the basis of the favourable results
obtained in cryptococcal meningitis. Endocarditis
treatment classically combines heart surgery with
either AmBD or LAmB and flucytosine. The
recommendations for the initial treatment of
hepatosplenic candidiasis are based on AmBD
or LAmB, possibly in association with flucytosine
for unstable patients, and fluconazole for stable
patients [15].
Hence, LAmB still serves as an alternative
treatment option for candidaemia in patients with
renal impairment or those receiving concomitant
nephrotoxic drugs, and in children with candida-
emia. For Candida meningitis or endocarditis, an
association with flucytosine should be considered.
LIPOSOMAL AMPHOTERICIN B AND
INVASIVE ASPERGILLOSIS ( IA)
Voriconazole has now become the treatment of
choice for IA, based on the results of a double-
blind multicentre trial that compared voricona-
zole with AmBD as a first-line treatment for the
infection [18]. Voriconazole showed superior effi-
cacy, with response rates at week 12 of 53% vs.
32% and a higher survival rate at the end of
treatment of 71% vs. 58% as compared with the
group that received AmBD. In addition, among
patients who were treated with AmBD as first-
line therapy and experienced failure or toxicity,
the response rate to second-line antifungal ther-
apy was only 19% [19]. Hence, most experts
currently agree that AmBD no longer has a role in
the management of IA in immunocompromised
hosts.
The first study that evaluated the efficacy of
LAmB in the treatment of IA was conducted in
1991 and was in a setting of so-called second-line
treatment for patients who failed to respond to or
were intolerant of other systemic antifungals.
Nine of 28 patients (32%) treated with LAmB,
given in doses between 0.5 and 5 mg ⁄ kg ⁄day,
were cured [8]. Subsequently, LAmB was com-
pared with AmBD as primary therapy for inva-
sive fungal infections (IFIs) in neutropenic
patients [20]. Patients in this trial received either
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LAmB 5 mg ⁄ kg ⁄day or AmBD 1 mg ⁄kg ⁄day for
14 days. Among a total of 53 patients with
suspected or documented pulmonary aspergillo-
sis, the response rates were 52% (13 ⁄ 25) and 29%
(8 ⁄ 28) in the LAmB and AmBD groups, respec-
tively [20]. In another first-line trial, Ellis and
colleagues compared two doses of LAmB, i.e., 1
and 4 mg ⁄ kg ⁄day, for the treatment of pulmo-
nary IA in 87 patients, and reported response
rates of 64% and 48%, respectively [21]. How-
ever, the clinical impact of this study was limited
by the small sample size. Under the assumption
that higher doses would be more effective, the
feasibility of administering very high doses of
LAmB for IA has been studied, and a pharmaco-
kinetic analysis of the results revealed that LAmB
pharmacokinetics are non-linear and do display a
maximal Cmax and area under the curve (AUC) at
the 10 mg ⁄ kg ⁄day dose, which was well-tolerated
[22].
The safety and efficacy of LAmB given in a
standard dose of 3 mg ⁄ kg ⁄day were compared to
the effects of a high dose of 10 mg ⁄ kg ⁄day for
10 days followed by the standard dose; 95% of
the study population suffered from IA, which was
localised to the lungs in 90% of cases. The results
of this ‘AmBiload’ trial were published recently
[23]. The response rates at the end of treatment
were 46% for those receiving the high loading
dose and 50% for those treated with the standard
dose. The 10 mg ⁄ kg ⁄day dose was associated
with a significantly higher rate of hypokalaemia,
i.e., 30% vs. 16%, and an increased nephrotoxicity
rate of 31% vs. 14%. Therefore, on the basis of this
trial, a high-dose LAmB regimen cannot be
recommended for first-line treatment of invasive
pulmonary aspergillosis. Whether or not higher
doses of LAmB might be of benefit in particular
cases of IA, such as endocarditis, brain abscesses
or bone infections, remains to be determined.
Patients with widespread disseminated asper-
gillosis might well benefit from higher doses of
LAmB.
Although comparison of data from two differ-
ent studies has serious limitations, it is interest-
ing to see that when considering first-line
treatment for IA, both the clinical responses for
voriconazole (53%) and for LAmB 3 mg ⁄ kg ⁄day
(50%), and the 3-month survival rates of 71%
and 72%, respectively, appear quite similar
[18,23]. On the basis of the data available,
voriconazole remains the drug of choice for the
treatment of IA, but in our opinion the ‘AmBi-
load’ study has validated LAmB at the standard
dose of 3 mg ⁄ kg ⁄day as a reasonable alternative,
at least for patients with a high likelihood of
major drug interactions, for patients with liver
insufficiency, and for those who are intolerant of
azoles [24]. Indeed, the 2008 IDSA Guidelines for
aspergillosis recommend that LAmB be used for
patients with IA where voriconazole is not
appropriate (A1 recommendation).
A recent prospective, randomised study evalu-
ated for the first time the putative efficacy of a
combination of two antifungals vs. monotherapy
as first-line treatment for IA. In this so-called
‘Combistrat trial’, LAmB at a dose of
10 mg ⁄ kg ⁄day was compared with a regimen of
LAmB 3 mg ⁄ kg ⁄day in combination with caspo-
fungin. Fifteen patients were included in each
arm. Response rates at day 14 and week 12 and
overall survival rates were similar in both arms of
the study, but the response rate at the end of
treatment was higher for combination therapy,
being 67% vs. 27% for the single agent (Caillot
DTA, Herbrecht R et al. Liposomal amphotericin B
in combination with caspofungin versus liposo-
mal amphotericin B high dose regimen for the
treatment of invasive aspergillosis in immuno-
compromised patients: randomised pilot study
(combistrat trial). Focus Fungal Infect 2006). In the
patients who had been treated with high-dose
LAmB, more nephrotoxicity (20% vs. 7%) was
found, as well as a higher number of infusion-
related reactions (20% vs. 0%), whereas there
was no difference between both arms in the rates
of hypokalaemia. Larger randomised studies are
required to explore the real potential of combi-
nation therapies. It is of note that echinocandins
do not penetrate well into the central nervous
system, and this may explain why caspofungin
given in combination with ABCD did not
enhance the efficacy of the polyene in an immu-
nodeficient mouse model of cerebral aspergillosis
[25,26].
LIPOSOMAL AMPHOTERICIN B AND
HISTOPLASMOSIS TREATMENT
Current treatment recommendations for severe
forms of disseminated histoplasmosis, in either
human immunodeficiency virus (HIV)-positive or
HIV-negative subjects, feature polyenes as first-
line therapy instead of itraconazole. For less
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severe cases, oral itraconazole constitutes an
appropriate treatment [25,26]. However, the use
of itraconazole is limited by several well-recogni-
sed problems such as numerous drug interac-
tions, variable intra- and inter-individual
digestive absorption and the lack of an easily
available intravenous formulation in Europe.
LAmB 3 mg ⁄ kg ⁄day should now be regarded
as first-line therapy for induction treatment of
disseminated histoplasmosis in AIDS patients.
Indeed, LAmB has been evaluated in a multicen-
tre randomised double-blind trial comparing
LAmB 3 mg ⁄ kg ⁄day (n = 55) with AmBD
0.7 mg ⁄ kg ⁄day (n = 26) for 2 weeks in AIDS
patients with disseminated histoplasmosis [28].
Induction treatment was followed by 10 weeks of
itraconazole consolidation treatment. Patients
treated with LAmB had a higher response rate
at the end of induction therapy (88% vs. 64%), as
well as a lower mortality rate (2% vs. 13%) with
fewer infusion-related side-effects (25% vs. 63%)
and less nephrotoxicity (9% vs. 37%). Mycolog-
ical response and response rates at the end of
consolidation therapy were similar in both groups
[27]. As the number of patients in the study was
rather low, the outcome has to be interpreted with
due caution. It should be noticed that this study
was the first to demonstrate a clear superior
activity of LAmB over AmBD in the treatment of
invasive mycoses. In addition, LAmB
3 mg ⁄ kg ⁄day and itraconazole were studied in a
trial that enrolled AIDS patients with a first
episode of disseminated histoplasmosis (median
CD4 cell count 20 ⁄mm3; 80% of patients with
positive blood culture). Response rates were
similar in both groups (86% and 88.5%), but
those who were given LAmB showed faster
fungal clearance and blood culture sterilisation
at week 2 (85% vs. 53%) as compared with
patients who received itraconazole. Histoplasma
antigen levels also decreased more rapidly under
treatment with LAmB ()1.6 U vs. )0.1 U) [28].
LIPOSOMAL AMPHOTERICIN B AND
CRYPTOCOCCOSIS TREATMENT
A combination of AmBD 0.7–1 mg ⁄ kg ⁄day and
flucytosine is generally regarded as the preferred
treatment for cryptococcal meningitis in both HIV-
positive and HIV-negative patients [29]. When
AmBD and flucytosine are used simultaneously,
faster fungal clearance of the cerebrospinal fluid
(CSF) is seen [29]. This classic finding has been
corroborated in a recent prospective study, where
it was shown that after 2 weeks of treatment, CSF
sterilisation was impaired and delayed in HIV-
infected patients with cryptococcal meningitis
who did not receive the combination as induc-
tion therapy [30]. Furthermore, not giving flucy-
tosine during induction therapy appeared to be
associated with a higher subsequent relapse rate
[31].
In a randomised trial in a similar category of
patients, the efficacy in patients with cryptococcal
meningitis of treatment for 3 weeks with AmBD
at a dose of 0.7 mg ⁄kg ⁄day (n = 13) was com-
pared with 4 mg ⁄ kg ⁄day LAmB (n = 15), fol-
lowed by a 400 mg ⁄day fluconazole regimen
[32]. The preliminary results of this study indi-
cated faster CSF sterilisation in the LAmB group
than in the AmBD group, in association with a
higher rate of negative CSF cultures at day 7 (40%
vs. 8%), day 14 (67% vs. 11%) and day 21 (73%
vs. 37%). However, the clinical response rates
were similar (86% vs. 80%) in both groups. CSF
sterilisation rates were very low, at 67% and 11%,
respectively, on day 14.
A still unpublished randomised double-blind
trial in 267 AIDS patients with cryptococcal
meningitis compared LAmB 3 mg ⁄kg ⁄day with
LAmB 6 mg ⁄kg ⁄day or AmBD 0.7 mg ⁄ kg ⁄day
[34]. Mycological responses were achieved in 64%
of patients who were treated with 3 mg ⁄ kg ⁄day
LAmB, in 54% with 6 mg ⁄ kg ⁄day LAmB, and in
54% with AmBD. Thus, the study suggests that
LAmB is at least as effective as AmBD in the
treatment of cryptococcal meningitis in AIDS
patients, while it is better tolerated, as evi-
denced by a less frequent occurrence of renal
failure and immediate infusion-related toxicity
in the LAmB group. However, the combination
of LAmB with flucytosine has not yet been
investigated.
The current IDSA guidelines designate LAmB
as being potentially useful in the treatment of
cryptococcal meningitis in cases of renal dysfunc-
tion [31]. It is our view that LAmB is indicated in
the treatment of cryptococcal meningitis and that
it should be used, in combination with flucyto-
sine, in cases of pre-existing renal impairment or
concomitant use of nephrotoxic agents, as renal
toxicity induced by AmBD may facilitate subse-
quent accumulation of flucytosine, which may
lead to serious haematological toxicity.
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LIPOSOMAL AMPHOTERICIN B AND
ZYGOMYCOSIS TREATMENT
Prospective therapeutic trials on the treatment of
zygomycosis have not been reported. However,
data in summary form are available, originating
from case reports or small restrospective series
that used variable and different criteria for eval-
uation of the response (Table 2). Most of the new
antifungals, including echinocandins and vorico-
nazole, are not active against Zygomycetes [33],
whereas polyenes and posaconazole display, at
least in vitro, activity against organisms belonging
to the Zygomycota group [34]. Posaconazole has
limited activity against certain of the Zygomyce-
tes. In a murine model of zygomycosis, posaco-
nazole showed partial efficacy against Absidia
corymbifera and a dose-dependent response effect
in mice infected with Rhizopus microsporus [34].
After its activity against Zygomycetes in vitro and
in animals had been established, the clinical
potential of posaconazole in patients with zygo-
mycosis was retrospectively evaluated in two
studies where the drug was given as second-line
therapy in individuals who had been treated with
other antifungals that were not tolerated or had
an insufficient effect. Response rates of 60% in 91
patients and 79% in 24 patients, respectively,
were reported [35,36]. It should be remembered
that posaconazole can only be administered orally
and carries the risk of drug–drug interactions that
are typical for the azole class of antifungal
compounds [37]. Moreover, steady-state plasma
levels are only obtained after 7–10 days of treat-
ment [38]. Without representative data on first-
line treatment, posaconazole should not be used
as first-line treatment of zygomycosis. Only when
an intravenous formulation becomes available can
a clinical trial that compares posaconazole with
LAmB be performed, leading to a possible change
in the future role of these drugs in the manage-
ment of zygomycosis.
The options for and limitations of AmBD and
LAmB as first-line treatment of zygomycosis have
been assessed in several retrospective analyses.
The first retrospective series covered the period
between 1987 and 2001, comprised 51 patients
with haematological malignancies, and showed a
23% response rate among 39 patients treated with
AmBD at a dose of 1 mg ⁄kg ⁄day, and a 58%
response rate in patients who received LAmB at
the standard dose level of 3 mg ⁄ kg ⁄day [39]. The
second, smaller retrospective series reported a
response rate of two of six patients treated with
AmBD, while one of two patients treated with
LAmB responded [40]. A recent large retrospec-
tive survey, which included all cases of zygomy-
cosis that had been described in the literature,
reported a 61% survival rate for AmBD as
compared with 69% for LAmB [40].
Two other retrospective studies evaluated the
efficacy and safety of the alternative lipid formu-
lations of amphotericin B in the setting of second-
line treatment of zygomycosis. The series of
patients treated with ABLC at a dose of
5 mg ⁄ kg ⁄day was characterised by a wide variety
of risk-factors and showed a 75% response rate
for this drug [41]. ABCD given in doses between 2
and 6 mg ⁄ kg ⁄day accomplished an objective
response in 60% of cases [42].
In summary, it can be stated that the lipid
derivatives of amphotericin B are probably more
effective and better tolerated than AmBD in the
treatment of zygomycosis. Whether higher dos-
ages of LAmB would be of benefit for this
indication remains obscure. Indeed, the AUC of
LAmB is maximal at a dose rate of 10 mg ⁄kg ⁄day;
at this level, the drug can saturate mononuclear
cells and allow a higher accumulation of ampho-
tericin B in the lungs, which are major targets of
infection by the agents of zygomycosis [22].
Moreover, high doses of LAmB were able to
attain a clinical response in patients who failed to
respond to conventional dosages [43,44]. The
Table 2. Retrospective studies evaluationg liposomal amphotericin B during zygomycosis
Reference Study Patients Treatment Number Response Survival
[40] First-line treatment Haematological malignancies LAmB 3 mg ⁄ kg ⁄day
AmBD 1 mg ⁄ kg ⁄day
12
39
58%
23%
20% (month 3)
[41] First-line treatment Haematological malignancies LAmB 3–5 mg ⁄ kg ⁄day
AmBD 1 mg ⁄ kg ⁄day
2
6
50%
33%
37%
[68] First- or second-line treatment Diverse underlying diseases LAmB
AmBD
116
532
69%
61%
AmBD, amphotericin B colloidal dispersion; LAmB, liposomal amphotericin B
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‘Ambiload’ trial [23] did not support the possible
superiority of 10 mg ⁄kg ⁄day over 3 mg ⁄ kg ⁄day
LAmB for first-line treatment of invasive fila-
mentous fungal infections, but this trial included
only three patients with zygomycoses who
received 10 mg ⁄ kg ⁄day LAmB. In an attempt to
provide an answer to the question of adequate
dosing, we have started a prospective national
phase II multicentre study (‘Ambizygo’ trial) to
evaluate the maximally effective and tolerated
dose of LAmB (up to 10 mg ⁄ kg ⁄day) as first-line
treatment of zygomycosis in adults and children.
In our view, LAmB given in high doses
represents an effective first-line treatment for
zygomycosis.
EMPIRICAL THERAPY IN PATIENTS
WITH PERSISTENT FEBRILE
NEUTROPENIA
Empirical treatment with AmBD in febrile neu-
tropenic patients became broadly accepted on the
basis of the outcome of two randomised trials,
and it was believed that such a strategy was able
to reduce the frequency of proven invasive fungal
infections [45,46]. Pizzo et al. randomised neu-
tropenic patients with persisting unexplained
fever despite broad-spectrum antibiotic therapy
into three arms: a group in which all antibiotic
therapy was terminated; a group that received
empirical AmBD as an additional treatment; and
a last group that continued antibacterial therapy
without any antifungal therapy. Patients who
received empirical antifungal therapy had a more
favourable clinical course than those in whom
antibiotics were continued with respect to reso-
lution of fever (68% vs. 53%) and a lower
incidence of IFI (1% vs. 9%) [46]. The second
classic trial in an antibiotic-refractory febrile
neutropenic population compared the outcome
of a group of patients who received AmBD
empirically with that of a group who were not
given any antifungal. Infections occurred in six of
16 unprotected patients as compared to two of 18
patients who received empirical antifungal treat-
ment [45]. However, both studies have serious
limitations, namely: only a small number of
patients was included, which did not allow a
statistically solid conclusion, and there was no
evidence for either an improvement in survival
rates or a significant decrease in the incidence of
invasive fungal infections. Despite these limita-
tions, empirical antifungal therapy for neutrope-
nic patients with fever that persists despite
broad-spectrum antibacterial therapy has become
generally accepted. However, with modern
diagnostic tools such as testing for the presence
of Aspergillus galactomannan antigen, fungal
DNA and b-glucan, as well as the utility of
high-resolution computed tomography scans,
it is possible to diagnose IFI at an earlier stage
of development. As a result, a pre-emptive
antifungal treatment strategy is a realistic treat-
ment option, particularly among adults,
that will figure more prominently in the future
[47].
Three major non-inferiority studies have
assessed the role of LAmB in the management
of persistent fever in neutropenic patients.
Initially, LAmB was compared to AmBD in a
randomised multicentre trial [48]; 343 patients
were treated with 3 mg ⁄ kg ⁄day LAmB and 344
patients with 0.6 mg ⁄kg ⁄day AmBD. To be
eligible, patients had to be febrile for at least
5 days in spite of adequate antibiotic therapy
and neutropenic with a neutrophil count
<500 ⁄mm3. After enrolment, therapy was con-
tinued until resolution of neutropenia. The
overall response was evaluated on the basis of
a five-point composite score and appeared to be
similar in both groups (50% vs. 49%). A sub-
analysis revealed that there were fewer break-
through fungal infections in the LAmB-treated
group than in the AmBD group (3% vs. 8%) and
strikingly fewer renal toxicity- and infusion-
related reactions [48]. In the second multicentre
non-inferiority randomised trial, 3 mg ⁄ kg ⁄day
LAmB was compared to intravenous voriconaz-
ole 6 mg ⁄kg twice-daily on the first day, fol-
lowed by 3 mg ⁄kg twice-daily on subsequent
days [49]. Success rates for LAmB and vorico-
nazole (31% vs. 26%), as well as the 7-day
survival rate, were similar (94% vs. 92%) for
both arms but significantly more breakthrough
fungal infections occurred in patients receiving
LAmB (5% vs. 2%). The main objective of the
trial, i.e., the demonstration of non-inferiority for
voriconazole in comparison with LAmB, was not
met, and therefore voriconazole failed to qualify
as an alternative candidate for the empirical
antifungal treatment of neutropenic patients.
Finally, a dose of 3 mg ⁄kg ⁄day LAmB was com-
pared to caspofungin at a starting dose of 70 mg
on day 1, followed by 50 mg ⁄day in the only
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double-blind multicentre non-inferiority rando-
mised trial [50]. Overall success rates, as as-
sessed by composite score, were similar for both
groups (34% vs. 34%), with a similar number of
breakthrough fungal infections. Caspofungin
was better tolerated, was associated with fewer
cases of infusion-related toxicity and was less
nephrotoxic.
LAmB given for empirical purposes has also
been compared to ABLC, the other commonly
available lipid formulation of amphotericin B, in
a multicentre double-blind randomised trial
[13]. Patients with fever and neutropenia
received either 3 mg ⁄ kg ⁄day LAmB (n = 85), or
5 mg ⁄kg ⁄day LAmB (n = 81), or 5 mg ⁄ kg ⁄day
ABLC (n = 78). The response rates to the three
different drug regimens were similar, namely
42%, 40%, and 33%, respectively. Infusion-
related adverse reactions were more frequent
when ABLC was given, and amounted to 88%,
as compared with 52% and 48% for LAmB, but
the differences between the regimens were even
more pronounced with respect to nephrotoxicity,
as a two-fold increase of creatinine serum level
occurred in 14%, 14% and 42% of cases, respec-
tively.
Although LAmB has a broader antifungal spec-
trum of activity than the other recommended
option, caspofungin, caution is required with
regard to potential nephrotoxicity, particularly
in allogeneic bone marrow transplant recipients.
On the other hand, the use of caspofungin has
been associated with breakthrough fungal infec-
tions caused by rare moulds and yeasts, such as
zygomycosis [51], trichosporonosis [52], scedos-
porinosis [53], Scopulariopsis brevicaulis infection
[54], and Aspergillus ustus infection [55]. On the
basis of its spectrum of activity and the results
obtained in large clinical trials, LAmB has to be
counted among the preferred antifungal agents
for empirical antifungal treatment in patients with
antibacterial-refractory, persisting fever during
neutropenia.
LIPOSOMAL AMPHOTERICIN B AS
POTENTIAL ANTIFUNGAL
PROPHYLAXIS IN HIGH-RISK
PATIENTS
Among specific high-risk populations, IFIs may
be extremely prevalent and are associated with a
high mortality rate. This particularly concerns
patients who are treated for acute leukaemia
(AL), and allogeneic stem-cell transplant (ASCT)
recipients. Over the last 15 years, fluconazole has
evolved as the classic antifungal prophylactic
drug for the prevention of yeast infections, but
this compound does not provide any coverage
against mould infections [56]. Although two
major recent studies have demonstrated the
efficacy of posaconazole prophylaxis in high-
risk populations during prolonged neutropenia
and graft vs. host disease, the lack of an
intravenous formulation and possible drug inter-
action issues may limit its use [57,58]. For cases
where an azole cannot be given, LAmB might
offer a reasonable alternative to prevent both
yeast and mould infections. To explore the
feasibility of this approach, several preliminary
studies that evaluated the safety of LamB in
a setting of prophylaxis have recently been
performed.
An open, prospective multicentre study, the
‘Prophysome trial’, evaluated the tolerance of
LAmB given as a weekly infusion at a dose of
10 mg ⁄ kg to 15 AL patients for 4 weeks and to
eight ASCT recipients for 8 weeks [59]. The AL
patients received a mean of three infusions,
whereas ASCT recipients only tolerated a mean
of 1.5. None of the patients treated for AL
required a reduction in dose or withdrawal of
the drug, but five of eight ACST recipients
required a decrease in dose or a treatment
interruption. The mean numbers of adverse
events per patient were 2.9 in AL patients and
7.2 in ACST recipients. Obviously, this novel
strategy appeared to be better tolerated in AL
patients, with transfusion-related reactions in
13% of cases and nephrotoxicity in 20% of
cases, than in ASCT recipients, who experienced
infusion-related reactions in 37% of cases and
nephrotoxiicity in 50% of cases. LAmB given at
a dose of 7.5 mg ⁄kg ⁄week for prophylactic
purposes was also evaluated in another study
that included 21 ACST recipients with acute
graft vs. host disease requiring corticosteroids
2 mg ⁄ kg ⁄day; the investigators classified toler-
ance as acceptable in 33% of patients who had to
stop the treatment because of adverse events
[60]. A third study conducted in a paediatric
population evaluated the tolerance and efficacy
of 3 mg ⁄ kg ⁄day LAmB given as prophylaxis
over 100 days post-ASCT in 51 children during a
hospital construction period. Thirty per cent of
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the patients required a decrease of the dose, and
in 11% treatment had to be interrupted because
of toxicity; 9.7% developed IFIs, four of which
were caused by Candida spp. and one by Tricho-
sporon. No invasive mould infections were seen
in these children, whereas five patients with a
low risk of mould infections who had been
nursed in an oncology unit without the protec-
tion of a prophylactically adminstered antifungal
developed IA [61].
LAmB is well-tolerated as antifungal prophy-
laxis in high-risk patients, at least in non-alloge-
neic bone marrow transplant patients, but the
definitive demonstration of its efficacy for this
indication is still awaited.
LIPOSOMAL AMPHOTERICIN B AND
LEISHMANIASIS
Visceral leishmaniasis (VL) is a major public
health concern in some parts of the world,
particularly in the Eastern Bihar region of India
and in South America. Therapeutic trials in non-
immunocompromised patients have mainly been
conducted in India. Pentavalent antimony-based
drugs have been the classic first-line therapy, but
their use is limited by cardiac toxicity, which
occurs in 8–17% of patients, and by the develop-
ment of resistance, which is responsible for a
disappointing success rate that presently ranges
from 36% to 69% in Bihar [62]. Different schemes
for the treatment of VL with LAmB have been
studied in HIV-negative patients. The first study
compared different regimens of short-course
treatment with LAmB in 88 immunocompetent
patients. In one study, 13 patients were treated
from day 1 to day 5 with 4 mg ⁄kg ⁄day LAmB
and showed a 100% cure rate at day 10, when a
total dose 24 mg ⁄ kg had been given; 42 patients
received 3 mg ⁄kg ⁄day for 6 days, with a 98%
cure rate at day 10 after a total dose of 18 mg ⁄ kg;
finally, 32 patients were treated with
3 mg ⁄ kg ⁄day from day 1 to day 5, with a 91%
cure rate at day 10 and a total dose of 15 mg ⁄ kg
[63]. On the basis of these results, the authors
recommended treating VL with a total dose of
LAmB of ‡20 mg ⁄ kg, to be given for 5 or more
days at a dose rate of 3–4 mg ⁄ kg ⁄day [64].
Interestingly, two trials assessed the feasibility
of a single high dose of LAmb in HIV-negative
patients suffering from VL, and both studies
demonstrated a high efficacy in combination with
good tolerance of a single dose of LAmB at dose
levels of 5 mg ⁄kg ⁄day and 7.5 mg ⁄ kg ⁄day, with
cure rates of 92% and 96%, respectively [63,65].
The number of studies in HIV-infected patients is
more limited. In a first-line therapy study, meg-
lumine antimoniate was compared with two
ABLC-based regimens at a dose level of
3 mg ⁄ kg ⁄day for 5 days and 3 mg ⁄kg ⁄day for
10 days in 57 patients. The cure rates were
similar, and amounted to 37%, 33%, and 42%,
respectively, but ABLC was less toxic than the
antimoniate regimen. The evolution of VL in HIV-
infected patients is often complicated by frequent
relapses, even when the cellular immunity has
been restored [66]. LAmB is recommended as
first-line treatment for VL in both HIV positive
and HIV-negative patients. Secondary prophy-
laxis for VL is recommended in HIV-infected
patients to reduce relapse rates, even in patients
with recent immune reconstitution, but the pre-
cise role of LAmB in this context remains to be
established.
CONCLUSION
In summary, LAmB can be used as an useful
alternative in the treatment of candidaemia in
patients with renal impairment or where there is
concomitant use of nephrotoxic drugs, as well as
for the treatment of Candida meningitis and
endocarditis; in the latter cases, a combination
with flucytosine appears to be attractive.
LAmB is currently the first-line therapy for
disseminated histoplasmosis in HIV-positive or
HIV-negative patients, and for cryptococcal men-
ingitis treatment in patients with renal impair-
ment. The drug is very useful for the treatment
of invasive aspergillosis in cases where there is a
risk of potential major drug–drug interactions,
and for patients with liver insufficiency or azole
intolerance. When zygomycosis is present or
likely, a high dose should be administered.
Owing to its broad antifungal spectrum, LAmB
is perfectly suited for empirical treatment of
persisting febrile neutropenia. It is of interest
that LAmB tolerance has also been well-demon-
strated in paediatric patients, including preterms
infants, and the drug is effective against candi-
daemia in children. In conclusion, based on
results of several randomised prospective trials,
the LAmB deserves a major place in the 2008
antifungal armamentarium.
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